Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gemcitabine triphosphate nanoparticle - pHion Therapeutics

Next Previous
X
Search
Drug Profile

Gemcitabine triphosphate nanoparticle - pHion Therapeutics

Alternative Names: PTX-C1; PTX_C1; RALA-gemcitabine-triphosphate(dFdCTP) nanoparticle

Latest Information Update: 02 Sep 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator pHion Therapeutics
  • Class Amines; Antineoplastics; Deoxyribonucleosides; Fluorinated hydrocarbons; Ketones; Pyrimidine nucleosides; Pyrimidines; Small molecules
  • Mechanism of Action Antimetabolites; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Pancreatic cancer

Most Recent Events

  • 29 Jun 2022 Gemcitabine triphosphate nanoparticle - pHion Therapeutics is available for licensing as of 27 Jun 2022. https://www.phiontx.co.uk/partnership
  • 27 Jun 2022 Preclinical trials in Pancreatic cancer in United Kingdom (unspecified route) before June 2022 (phion Therapeutics website, June 2022)
  • 20 Apr 2022 phion Therapeutics receives patent protection for technology in Spain

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top